GTCR and Corza Health’s €350 Million Acquisition of TachoSil Surgical Patch


Kirkland represented GTCR and Corza Health, Inc., while Linklaters acted as Takeda’s legal advisor in this transaction.

Takeda Pharmaceutical Company Limited (“Takeda”) has entered into an agreement to divest its TachoSil® Fibrin Sealant Patch (“TachoSil®”) to Corza Health, Inc. (“Corza Health”).

Corza Health was formed in 2019 as a partnership between private equity firm GTCR and healthcare industry veteran Gregory T. Lucier to build a market-leading healthcare business with a particular focus on the broader medical technology and life sciences sector.

Takeda will receive €350 million in cash upon closing of the transaction, which is subject to customary legal and regulatory closing conditions.

TachoSil® is a surgical patch trusted by medical professionals globally to deliver safe, fast and reliable bleeding control.

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to bringing Better Health and a Brighter Future to patients by translating science into highly-innovative medicines. T

Nomura acted as financial advisor to Takeda.

The Kirkland team was led by transactional partners Jacob Traff (Picture), Christopher Thomas, Michael Weed, Sanford Perl and David Higgins.

Involved fees earner: David Higgins – Kirkland & Ellis; Sanford Perl – Kirkland & Ellis; Christopher Thomas – Kirkland & Ellis; Jacob Traff – Kirkland & Ellis; Michael Weed – Kirkland & Ellis;

Law Firms: Kirkland & Ellis;

Clients: Corza Health; GTCR;